Screener
Cytokinetics CYTK EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Cytokinetics’s reported figures.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's EBITDA?
- Cytokinetics (CYTK) reported EBITDA of -$175.54M in Q2 2026.
- How has Cytokinetics's EBITDA changed year-over-year?
- Cytokinetics's EBITDA decreased by 60.7% year-over-year, from -$109.22M to -$175.54M.
- What is the long-term trend for Cytokinetics's EBITDA?
- Over 4 years (2021 to 2025), Cytokinetics's EBITDA has grown at a 34.5% compound annual growth rate (CAGR), from -$184.04M to -$602.13M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Cytokinetics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude